Desonide
Desonide, Desowen, Tridesilon (desonide) is a small molecule pharmaceutical. Desonide was first approved as Tridesilon on 1982-01-01. It is used to treat facial dermatoses, foot dermatoses, hand dermatoses, inflammation, and leg dermatoses amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Desonide, Desowen (discontinued: Desonate, Desonide, Verdeso)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Desonide
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| desonate | New Drug Application | 2010-11-08 |
| desonide | ANDA | 2024-12-31 |
| desonide ointment, 0.05% | ANDA | 2024-12-16 |
| desowen | ANDA, New Drug Application | 2019-01-28 |
| lokara | ANDA | 2013-11-22 |
| tridesilon cream | New Drug Application | 2016-04-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| inflammation | MP_0001845 | D007249 | — |
| facial dermatoses | — | D005148 | — |
| foot dermatoses | — | D005533 | — |
| hand dermatoses | — | D006229 | — |
| scalp dermatoses | — | D012536 | — |
| leg dermatoses | — | D007868 | — |
Agency Specific
FDA
EMA
No data
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB08: Desonide
— D07B: Corticosteroids, combinations with antiseptics
— D07BB: Corticosteroids, moderately potent, combinations with antiseptics
— D07BB02: Desonide and antiseptics
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA11: Desonide
HCPCS
Code | Description |
|---|---|
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg |
| J7627 | Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg |
| J7633 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligram |
| J7634 | Budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligram |
Clinical
No data
Drug
General
| Drug common name | Desonide |
| INN | desonide |
| Description | Desonide (INN) is a low-potency topical corticosteroid anti-inflammatory that has been available since the 1970s. It is primarily used to treat atopic dermatitis (eczema), seborrheic dermatitis, contact dermatitis and psoriasis in both adults and children. It has a fairly good safety profile and is available as a cream, ointment, lotion, and as a foam under the tradename Verdeso Foam. Other trade names for creams, lotions, and ointments include Tridesilon, DesOwen, Desonate. It is a group VI corticosteroid under US classification, the second least potent group.
|
| Classification | Small molecule |
| Drug class | topical steroids (acetal derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1 |
Identifiers
| PDB | — |
| CAS-ID | 638-94-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201109 |
| ChEBI ID | 204734 |
| PubChem CID | 12536 |
| DrugBank | DB01260 |
| UNII ID | J280872D1O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Desonide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use